On February 20, 2026, the U.S. Food and Drug Administration (FDA) approved Bysanti (milsaperidone) tablets for the treatment of acute manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults, marking a significant advancement in psychiatric therapeutics.
Bysanti is designated as a new chemical entity (NCE), expanding the atypical antipsychotic class with a profile linked to decades of clinical experience through its active metabolite. This approval offers clinicians and patients an additional evidence-based tool to address severe mood and psychotic symptoms, and it may lay the foundation for future indications, including adjunctive treatment in major depressive disorder.
Why This Approval Matters
Bipolar I disorder and schizophrenia are chronic, debilitating conditions with complex symptomatology that often require lifetime management. Effective antipsychotic medications are central to stabilizing mood, reducing psychosis, and preventing relapse. While several antipsychotics are currently available, continued innovation is critical to expand treatment choices, improve tolerability, and enhance patient outcomes.
Bysanti’s approval represents:
By building on existing evidence while offering a distinct regulatory pathway and long-term exclusivity, Bysanti may help address unmet needs in clinical practice.
What Is Bysanti (Milsaperidone)?
Bysanti (milsaperidone) is an oral atypical antipsychotic that works by antagonizing key receptors involved in mood, psychosis, and arousal, including:
These actions contribute to its therapeutic effects in both bipolar I disorder and schizophrenia. Milsaperidone is structurally related to iloperidone, a previously approved antipsychotic, and is believed to interconvert to iloperidone in the body, offering a bioequivalent clinical profile supported by a robust dataset from more than 100,000 patient-years of clinical experience.
Clinical Implications
Bysanti is approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder. These episodes are often disruptive and dangerous, requiring rapid symptom control. An effective antipsychotic option provides clinicians with choice and flexibility, particularly for patients who may not tolerate or respond to other agents.
Schizophrenia affects approximately 1 % of adults and remains a leading cause of disability worldwide. Bysanti adds to the therapeutic armamentarium for psychosis, especially for patients who have struggled with symptoms despite existing treatment options.
Vanda Pharmaceuticals is currently conducting a Phase III trial evaluating Bysanti as a once-daily adjunctive treatment for treatment-resistant major depressive disorder (MDD), with results expected by the end of 2026. If successful, this could represent a significant expansion of its clinical utility.
Safety and Tolerability
Because Bysanti rapidly converts to iloperidone in vivo, its safety profile is similar to that of iloperidone. Common adverse reactions seen with atypical antipsychotics — such as dizziness, somnolence, orthostatic hypotension, weight changes, and metabolic effects — are considerations in clinical decision-making, necessitating careful monitoring, especially in patients with cardiometabolic risk factors.
Clinicians should review the full prescribing information, including boxed warnings and contraindications, when initiating treatment.
The Broader Innovation Context
Bysanti is the second FDA approval for Vanda Pharmaceuticals in a short period, following the recent approval of Nereus™ (tradipitant) in late 2025. Its status as a new chemical entity, combined with patent protection extending into the 2040s, supports long-term development and patient access strategies.
By preserving a pathway for ongoing research and clinical exploration — including its use in mood disorders — Bysanti exemplifies the continuous need for pharmacologic innovation in psychiatric care.
Looking Ahead
The approval of Bysanti reinforces several key themes in contemporary psychiatry:
As psychiatric medicine evolves toward more personalized and mechanism-based approaches, new agents such as Bysanti offer fresh avenues for improving symptomatic control, functional recovery, and quality of life for patients facing severe psychiatric illness.
References
Contacts
Request for Second Opinion Form: https://Go.uth.edu/CIPIntake (external link)
Phone: (713) 486-2621
Fax: (713) 500-2728
E-mail: [email protected]
Website: https://go.uth.edu/CIP (external link)
Disclaimer
This article was created with the assistance of artificial intelligence (AI) to enhance clarity and readability. All medical and scientific content has been reviewed and approved by Joao L. de Quevedo, MD, PhD, Director of the Center for Interventional Psychiatry at the John S. Dunn Behavioral Sciences Center at UTHealth Houston. This content is for educational purposes only and does not substitute for professional medical advice.